A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Purdue Pharma
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.
- 25 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.